Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Fred Hutchinson Cancer Center
New Approaches to Neuroblastoma Therapy Consortium
Case Comprehensive Cancer Center
UNICANCER
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
The University of Texas Health Science Center at San Antonio
University of California, San Francisco
Jubilant DraxImage Inc.
New Approaches to Neuroblastoma Therapy Consortium
miRagen Therapeutics, Inc.
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
University of California, San Francisco
University of Wisconsin, Madison
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
University of Michigan Rogel Cancer Center
City of Hope Medical Center
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Methodist Hospital Research Institute
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Duke University
Angimmune LLC
University of Turin, Italy
Peter MacCallum Cancer Centre, Australia
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)